Effect of statins on soluble CD40 ligand in hypercholesterolemic Type 2 diabetic patients.
Hypercholesterolemia and Type 2 diabetes are well-recognized risk factors for cardiovascular disease, promoted by a condition of subclinical inflammation and a hypercoagulable state. Soluble CD40 ligand (sCD40L), a marker of vascular inflammation, seems to predict vascular damage in patients with Type 2 diabetes. Beside the lipid-lowering effect, statins seem to slow the progression of atherosclerosis through a series of anti-inflammatory effects, including a reduction of sCD40L levels. This study compared the effect of a short-term (12 weeks) treatment with rosuvastatin or simvastatin on some markers of inflammation in 36 patients with Type 2 diabetes and moderate hypercholesterolemia. As expected, both drugs significantly modified lipid profile; moreover, rosuvastatin and simvastatin were both able to significantly reduce albumin excretion rate in these patients, without affecting urinary N-acetyl-beta-D-glucosaminidase. Serum homocysteine was not influenced by the treatment, as interleukin-6 levels, while C reactive protein diminished; moreover, rosuvastatin, but not simvastatin, was able to significantly reduce sCD40L. The only clinical parameter related with the variations in sCD40L was systolic blood pressure. In hypercholesterolemic Type 2 diabetic patients, sCD40L, a factor playing a pivotal role in the pathogenesis of atherosclerosis and associated with more rupture-prone lesions, is reduced by short-term treatment with rosuvastatin.
Santini
E
E
Department of Internal Medicine, University of Pisa, I-56100 Pisa, Italy.
Madec
S
S
Corretti
V
V
Ferrannini
E
E
Solini
A
A
D000418:Albumins / Q000378:metabolism; D015415:Biomarkers / Q000378:metabolism; D001794:Blood Pressure; D023201:CD40 Ligand / Q000097:blood*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005464:Fluorobenzenes / Q000627:therapeutic use*; D006710:Homocysteine / Q000097:blood; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy; D015850:Interleukin-6 / Q000097:blood; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D011743:Pyrimidines / Q000627:therapeutic use*; D000068718:Rosuvastatin Calcium; D019821:Simvastatin / Q000627:therapeutic use*; D013449:Sulfonamides / Q000627:therapeutic use*
D000418:Albumins; D015415:Biomarkers; D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D015850:Interleukin-6; D008055:Lipids; D011743:Pyrimidines; D013449:Sulfonamides; D006710:Homocysteine; D023201:CD40 Ligand; D000068718:Rosuvastatin Calcium; D019821:Simvastatin
Atherosclerosis. 2007 Sep;194(1):230-7
16965776
Circulation. 2004 Jun 1;109(21 Suppl 1):II2-10
15173056
Heart. 2001 Dec;86(6):649-55
11711459
Clin Cornerstone. 2006;8 Suppl 1:S21-7
16903166
Atherosclerosis. 2007 Jan;190(1):205-11
16500662
Clin Ther. 2007 Feb;29(2):242-52
17472817
Cardiol Clin. 2004 Nov;22(4):511-26
15501620
Circulation. 2003 Sep 2;108(9):1049-52
12912804
Diabetes Metab Res Rev. 2006 Jan-Feb;22(1):4-10
15991254
Am J Cardiol. 2006 Jan 16;97(2A):33A-41A
16442935
Am J Cardiol. 2007 Jun 15;99(12):1706-1713
17560879
Kidney Int. 2006 Jul;70(1):177-86
16710349
J Nephrol. 2005 Sep-Oct;18(5):559-67
16299682
Circulation. 2004 Nov 23;110(21):3349-54
15520323
Curr Vasc Pharmacol. 2006 Jul;4(3):175-83
16842135
Pharmacol Res. 2006 Dec;54(6):421-8
17011788
J Am Coll Cardiol. 2007 Feb 6;49(5):554-61
17276178
Atheroscler Suppl. 2006 Apr;7(1):31-5
16503422
Cell Mol Life Sci. 2001 Jan;58(1):4-43
11229815
Am J Cardiol. 2004 Jul 15;94(2):157-61
15246890
JAMA. 2001 Jul 4;286(1):64-70
11434828
Circulation. 2004 Jun 1;109(21):2524-8
15136493
Thromb Haemost. 2001 Jan;85(1):47-51
11204586
Circulation. 2005 Feb 1;111(4):412-9
15687128
Circulation. 2000 Apr 18;101(15):1767-72
10769275
Clin Chim Acta. 2005 May;355(1-2):191-6
15820495
Am J Ther. 2007 Jan-Feb;14(1):41-5
17303974
Int J Biochem Cell Biol. 2000 Jul;32(7):687-93
10856699
Am J Cardiol. 2006 Dec 15;98(12):1656-9
17145229
Circulation. 2001 Feb 20;103(7):926-33
11181465
Arterioscler Thromb Vasc Biol. 2001 Nov;21(11):1712-9
11701455
N Engl J Med. 2003 Mar 20;348(12):1104-11
12646667
Circulation. 2004 Jun 1;109(21 Suppl 1):II18-26
15173059
Arterioscler Thromb Vasc Biol. 2005 Jun;25(6):1231-6
15790934
Arterioscler Thromb Vasc Biol. 2001 Jan;21(1):115-21
11145942
Angiology. 2006 Mar-Apr;57(2):211-8
16518530
Arch Intern Med. 2006 Nov 27;166(21):2307-13
17130382
J Clin Pharmacol. 2003 Aug;43(8):825-30
12953339
J Chromatogr. 1987 Nov 27;422:43-52
3437026